Feasibility of teleyoga for people with post COVID-19 condition- a mixed method design.

Publication date: Jan 08, 2025

Evidence about rehabilitation of post COVID-19 condition is scarce. Yoga has been found beneficial in other chronic conditions and can be delivered in a digital format at home. The aim of the study was to explore the feasibility of teleyoga in persons with post COVID-19 condition by assessing adherence, safety, limited efficacy and experiences. Pre-post mixed-method design. Participants were recruited from a post COVID-19 rehabilitation clinic. The intervention included standardised live-streamed teleyoga sessions twice/week for 7 weeks and individual yoga using a digital application during 12 weeks. Adherence to the teleyoga intervention was measured by registration of participation and by analysing the log in the application. Safety was measured by registration of serious adverse events. Limited efficacy examined trends in the predicted direction for better outcome in patients with a post-COVID condition in the 6-minute walk test, gait speed, cognition, health-related quality-of-life, mental distress, sleep and exercise motivation. We also assessed patients’ experiences after the intervention. Nine women and 2 men were enrolled, aged between 27 and 61 years, and duration of post COVID-19 3-12 months. Adherence: Half of the participants participated in more than 50% of the online yoga sessions. They enjoyed the digital format and the social aspect of the online yoga sessions. Some participants experienced that the yoga sessions of 60 min were too long. People with post COVID-19 felt motivated to participate, however they felt conflicted when other commitments took time away from yoga. Adherence to the yoga application varied, 6 patients used it less than 50% of the recommended time. Persons with post COVID-19 experienced symptoms due to their disease, which could increase during the yoga sessions that made it harder to participate. There were no reported serious adverse events. Limited efficacy: Participants expressed that they breathed more consciously and experienced relaxation and reduction of stress and anxiety. After 7 weeks of teleyoga there was a significant improvement in cognitive function (p-value = 0. 048). No differences were found in the physical tests, health-related quality-of-life, anxiety and depression, sleep or in exercise motivation. Adherence to the online yoga sessions was quite low and might be improved with shorter yoga sessions. Online yoga was safe, but some participants experienced an increase in symptoms. Teleyoga was associated with improved cognition, breathing and relaxation. The results show that online yoga could be feasible for people post COVID-19, but adaptation of the yoga-program may be required, especially as many patients experience an increase of symptoms. Furthermore, the teleyoga should be more flexible with regards to the duration and the number of sessions. As few participants were adherent to the application, the relevance and usefulness of this needs to be further explored.

Open Access PDF

Concepts Keywords
Disease Feasibility study
Home Mixed method
Live Mobile application
Week Post covid-19 condition
Yoga Rehabilitation
Teleyoga
Videoconference
Yoga

Semantics

Type Source Name
disease MESH COVID-19
disease MESH chronic conditions
disease IDO intervention
drug DRUGBANK Tropicamide
disease MESH post-COVID condition
disease MESH gait
disease IDO quality
disease MESH anxiety
disease MESH depression
pathway REACTOME Reproduction
disease MESH infection
disease MESH syndrome
disease MESH complications
disease MESH dyspnea
disease MESH brain fog
disease MESH confusion
disease MESH sleep disorder
disease MESH hair loss
disease MESH postures
disease MESH heart failure
disease MESH chronic fatigue syndrome
disease IDO blood
disease MESH spondylitis
disease MESH COPD
disease MESH heart disease
disease MESH lung disease
disease IDO symptom
drug DRUGBANK Aspartame
disease MESH cognitive impairment
drug DRUGBANK Cysteamine
disease MESH comorbidity
disease MESH Insomnia
drug DRUGBANK Etoperidone
drug DRUGBANK Ilex paraguariensis leaf
disease MESH hyperventilation
disease MESH privacy
disease IDO process
disease MESH burnout
disease MESH breast cancer
pathway KEGG Breast cancer
drug DRUGBANK Troleandomycin
disease MESH Cancer
disease MESH Anxiety Disorders
disease MESH ankylosing spondylitis
disease MESH Central Sensitization

Original Article

(Visited 1 times, 1 visits today)